Articles from Adverse Event Reporting News (February 12, 2008)

Title	Author	Type	Words
Baxter's multiple-dose vial heparin linked to severe allergic reactions.			641
Clinical investigator re-inspection nets clean inspection report.			408
Connecticut investigates marketing of Vytorin and Zetia.		Brief article	299
Daiichi drug backed with restrictions.			475
FDA panel backs longer-lasting Zyprexa.		Brief article	259
FDA recalls infusion pumps.		Brief article	164
FDA says Botox linked to children's deaths.			433
FDA to crack down on companies marketing injectable colchicines.			526
FDA warns of suicide risks associated with anti-epileptic medicines.			535
Federal grand jury investigates Merck's handling of Vioxx.		Brief article	257
Grassley accuses doctor of leaking information to GSK.			756
HHS proposes establishment of Patient Safety Organizations.			681
Lilly reportedly poised to settle Zyprexa probe.		Brief article	268
Maier slapped with 3-citation 483 for case history flaws, not reporting adverse events.			436
Major diabetes trial halted after deaths.			597
NuCel Labs eye drops and eye/ear washes recalled.		Brief article	127
Polypharmacy major factor in prescription drug deaths.			504
President Bush proposes about $97 million more for medical product safety, user fees for generics.	Mashaw, Rebecca		966
Safety labeling.			5275
Statins' effects on cognitive function under scrutiny.			725
Tainted drugs tied to Chinese supplier of abortion drug.			724